[144] Cellebrite DI Ltd. SEC Filing

Rhea-AI Filing Summary

Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 34,151 ordinary shares on 09/22/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $601,399.11 and 245,691,023 shares outstanding. The shares were acquired as 107,008 Restricted Stock Units on 09/19/2025 from Cellebrite DI Ltd. and were received as compensation. The filing indicates no reported sales by the seller in the past three months. Several filer identification fields in the public extract (CIK/CCC and contact details) are blank in the provided text.

Positive

• Planned sale disclosed under Rule 144, demonstrating compliance with securities resale reporting requirements
• Sale executed through a major broker (Morgan Stanley Smith Barney LLC), indicating standard institutional handling
• No reported sales in the prior three months by the seller, per the form's 'Nothing to Report' entry

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice for sale of recently vested RSUs; transaction appears procedural and not materially market-moving.

The filing documents a planned sale of 34,151 ordinary shares acquired as restricted stock units three days earlier and designated as compensation. The broker is Morgan Stanley Smith Barney LLC and the seller reports no other sales in the prior three months. Given the size relative to outstanding shares (34,151 vs 245,691,023), this is small in absolute and relative terms and therefore unlikely to affect market valuation. The filing lacks identifying filer CIK/CCC in the provided extract, which limits traceability.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; shows post-vesting disposition of compensation shares via a broker.

The notice states the securities were acquired as RSUs and will be sold through an institutional broker, consistent with standard executive or employee compensation monetization. The representation about lack of undisclosed material information is included as required. Absence of visible filer contact identifiers in this excerpt reduces transparency but does not invalidate the disclosure content shown.

09/22/2025 - 09:37 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, par value NIS 0.00001	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Floor New York NY 10004	34151	601399.11	245691023	09/22/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, par value NIS 0.00001	09/19/2025	Restricted Stock Units	Cellebrite DI Ltd.			107008	09/19/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Cellebrite's Form 144 (CLBT) report about the proposed sale?

It reports a proposed sale of 34,151 ordinary shares on 09/22/2025 through Morgan Stanley, with aggregate market value of $601,399.11.

How were the shares being sold acquired according to the filing?

The shares were acquired as 107,008 Restricted Stock Units on 09/19/2025 from Cellebrite DI Ltd., and the nature of payment is listed as compensation.

How large is the proposed sale relative to outstanding shares?

The form lists 245,691,023 shares outstanding; the proposed sale of 34,151 shares is a small portion of that total.

Does the filing show prior sales by the same person in the last three months?

The section for securities sold during the past three months states Nothing to Report.

Are filer identification details available in the provided excerpt?

No. The provided extract shows blank fields for filer CIK/CCC and contact details; those identifiers are not present in this text.